"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 6 | 12 |
| 1997 | 2 | 5 | 7 |
| 1998 | 3 | 9 | 12 |
| 1999 | 5 | 7 | 12 |
| 2000 | 2 | 5 | 7 |
| 2001 | 4 | 7 | 11 |
| 2002 | 5 | 13 | 18 |
| 2003 | 4 | 8 | 12 |
| 2004 | 2 | 8 | 10 |
| 2005 | 5 | 11 | 16 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 6 | 7 |
| 2008 | 6 | 12 | 18 |
| 2009 | 5 | 8 | 13 |
| 2010 | 2 | 7 | 9 |
| 2011 | 6 | 13 | 19 |
| 2012 | 10 | 12 | 22 |
| 2013 | 14 | 7 | 21 |
| 2014 | 13 | 13 | 26 |
| 2015 | 21 | 10 | 31 |
| 2016 | 14 | 17 | 31 |
| 2017 | 14 | 15 | 29 |
| 2018 | 19 | 14 | 33 |
| 2019 | 13 | 11 | 24 |
| 2020 | 24 | 17 | 41 |
| 2021 | 29 | 33 | 62 |
| 2022 | 5 | 59 | 64 |
| 2023 | 5 | 47 | 52 |
| 2024 | 28 | 15 | 43 |
| 2025 | 23 | 16 | 39 |
| 2026 | 14 | 8 | 22 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Impact of Low Community Circulation of Respiratory Syncytial Virus (RSV) on Immunity Debt Against RSV in Adults During the Coronavirus Disease 2019 Pandemic. J Infect Dis. 2026 Oct 15; 234(4):564-572.
-
Birth Cohort Effects in Adults Associated With Influenza A(H1N1)pdm09 Vaccine Effectiveness. J Infect Dis. 2026 Oct 15; 234(4):e802-e811.
-
Peripheral human mAb therapy yields modulation of neuroinflammation and long-term functional recovery from lyssavirus infection. Emerg Microbes Infect. 2026 Dec; 15(1):2736987.
-
ACE2-like Catalytic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies. Pathogens. 2026 Sep 04; 15(9).
-
Evaluation of Serum Antibodies as Correlates of Protection Against Norovirus Infection and Disease. J Infect Dis. 2026 Sep 02; 234(2):220-228.
-
Heritable transgenic schistosomes as a living platform for SARS-CoV-2 neutralizing antibody secretion. Nat Commun. 2026 08 26; 17(1).
-
Congenital Cytomegalovirus Infection in Fetal Demise: A Retrospective Cohort Study. Viruses. 2026 Aug 12; 18(8).
-
Evaluation of a multiantigen mRNA vaccine against EEHV1A in Asian elephants. J Virol. 2026 Aug 18; 100(8):e0038826.
-
First evidence of clinical protection from an EEHV1A mRNA vaccine in naturally infected juvenile elephants. J Virol. 2026 Aug 18; 100(8):e0218625.
-
A distinct E dimer epitope underlies selective recognition by a protective human West Nile virus antibody. EMBO Rep. 2026 08; 27(15):4583-4601.